Bone Therapeutics completed recruitment of 44 treated patients required for planned interim analysis of a Phase III trial for PREOB® autologous bone cell therapy in the treatment of osteonecrosis of the hip.
Results from one-year follow-up are expected in 3Q18, and if strong efficacy is documented, recruitment could be terminated prematurely.
The Phase III randomized, double-blind, placebo-controlled pivotal trial is investigating PREOB in early-stage osteonecrosis of the femoral head over two years.
Bone Therapeutics completed recruitment of 44 treated patients required for planned interim analysis of a Phase III trial for PREOB® autologous bone cell therapy in the treatment of osteonecrosis of the hip.
Results from one-year follow-up are expected in 3Q18, and if strong efficacy is documented, recruitment could be terminated...
Bone Therapeutics completed recruitment of 44 treated patients required for planned interim analysis of a Phase III trial for PREOB® autologous bone cell therapy in the treatment of osteonecrosis of the hip.
Results from one-year follow-up are expected in 3Q18, and if strong efficacy is documented, recruitment could be terminated prematurely.
The Phase III randomized, double-blind, placebo-controlled pivotal trial is investigating PREOB in early-stage osteonecrosis of the femoral head over two years.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
